DGAP-News: Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue Target and Outlines Vision for 2020 at Capital Markets Day 2014

Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue Target and Outlines Vision for 2020 at Capital Markets Day 2014

DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):

Sonstiges

Fresenius Medical Care AG & Co. KGaA Sets New Long-Term Revenue Target

and Outlines Vision for 2020 at Capital Markets Day 2014

04.04.2014 / 08:28

---------------------------------------------------------------------

Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the "company"

or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock

Exchange: FMS), the world's largest provider of dialysis products and

services, hosted a Capital Markets Day (CMD) on April 3 in New York.

The event was aimed at giving analysts and investors further insight into

Fresenius Medical Care's vision for 2020 and the growth and efficiency

strategies the company is pursuing. The CMD included presentations by chief

executive officer Rice Powell and other members of the senior management

team on global strategy, regional business strategies, R&D, manufacturing,

medical therapy and financials.

Long-term financial target

Fresenius Medical Care also announced its long-term financial target for

2020. Based on revenue of $14.6 billion in fiscal year 2013, the company

has set its ambitious revenue guidance for 2020 at $28 billion. This

represents a cumulative average growth rate of around 10% per annum (CAGR)

and a near doubling of revenue compared to 2013.

Global Efficiency Program

Participants at the CMD received an update on the company's Global

Efficiency Program. The program's objectives are to identify efficiency

potential, enhance the overall competitiveness of Fresenius Medical Care,

and free up resources for reinvestment. The company has several projects in

place that will achieve sustained efficiency gains over multiple years and

should lead to cost savings of $300 million per annum by 2017.

Continued strong growth in dialysis products and services

Fresenius Medical Care's world-leading position in the dialysis industry

has been built on its vision and capabilities in developing innovations

that shape the future of treatment for patients. Fresenius Medical Care

will continue to develop innovative products focused on quality outcomes

for the patient while expanding the company's dialysis products and

services around the world.

Extending care coordination for patients

In addition to strong growth in the underlying business of dialysis

products and services, Fresenius Medical Care sees significant potential in

a business area it began developing some years ago and now calls Care

Coordination. Care Coordination is an extension of the company's renal care

for its patients and currently includes e.g. vascular care, laboratory and

pharmacy businesses. Fresenius Medical Care plans to build this business

segment and expects revenue from Care Coordination to grow from 3% of total

revenue in 2013 to about 18% in 2020.

Rice Powell, chief executive officer of Fresenius Medical Care, commented

at the CMD: "The number of dialysis patients is expected to double in the

next seven years. We will continue to execute on our plan for growth and

efficiency across the business. Our vertically integrated business enables

us to provide the most effective and efficient care for these patients and

is the platform to expand our care coordination capabilities. We recognize

that moving beyond our core dialysis product and services business brings

areas with different risk and margin profiles, and we are convinced this is

reflected in our vision and guidance for 2020. With the acceleration in our

revenue growth going forward we should be able to generate earnings after

tax growth in the high single digits."

PDF versions of presentations and other information material given at the

Capital Markets Day can be found on our website:

http://www.fmc-ag.com/5119.htm

Fresenius Medical Care is the world's largest integrated provider of

products and services for individuals undergoing dialysis because of

chronic kidney failure, a condition that affects more than 2.5 million

individuals worldwide. Through its network of 3,250 dialysis clinics in

North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius

Medical Care provides dialysis treatments for 270,122 patients around the

globe. Fresenius Medical Care is also the world's leading provider of

dialysis products such as hemodialysis machines, dialyzers and related

disposable products.

For more information about Fresenius Medical Care, visit the company's

website at www.fmc-ag.com.

Disclaimer

This release contains forward-looking statements that are subject to

various risks and uncertainties. Actual results could differ materially

from those described in these forward-looking statements due to certain

factors, including changes in business, economic and competitive

conditions, regulatory reforms, foreign exchange rate fluctuations,

uncertainties in litigation or investigative proceedings, and the

availability of financing. These and other risks and uncertainties are

detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the

U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.

KGaA does not undertake any responsibility to update the forward-looking

statements in this release.

Ende der Corporate News

---------------------------------------------------------------------

04.04.2014 Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch die DGAP - ein Unternehmen der EQS Group AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber

verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,

Corporate News/Finanznachrichten und Pressemitteilungen.

Medienarchiv unter http://www.dgap-medientreff.de und

http://www.dgap.de

---------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Deutschland

Telefon: +49 (0) 6172- 609 2525

Fax: +49 (0) 6172- 609 2301

E-Mail: ir@fmc-ag.com

Internet: www.fmc-ag.de

ISIN: DE0005785802, DE0005785836,

WKN: 578580, 578583

Indizes: DAX

Börsen: Regulierter Markt in Frankfurt (Prime Standard);

Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,

München, Stuttgart; Terminbörse EUREX; NYSE

Ende der Mitteilung DGAP News-Service

---------------------------------------------------------------------

261618 04.04.2014